U.S. market Closed. Opens in 10 hours 41 minutes

TMDX | TransMedics Group, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 71.75 - 76.57
52 Week Range 58.27 - 177.37
Beta 2.52
Implied Volatility 69.00%
IV Rank 22.42%
Day's Volume 3,221,437
Average Volume 1,813,735
Shares Outstanding 33,561,500
Market Cap 2,538,256,245
Sector Healthcare
Industry Medical - Devices
IPO Date 2019-05-02
Valuation
Profitability
Growth
Health
P/E Ratio 81.32
Forward P/E Ratio N/A
EPS 0.93
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 584
Country USA
Website TMDX
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
*Chart delayed
Analyzing fundamentals for TMDX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is bad and Health is weak. For more detailed analysis please see TMDX Fundamentals page.

Watching at TMDX technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, but short-term trend is bullish. More technicals details can be found on TMDX Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙